Although there is scarce data on the use of ghrelin for cardiovascular disorders in human subjects, it was shown that intravenous administration of ghrelin for three weeks reduces arterial blood pressure, improves left ventricular function, work capacity and peak oxygen consumption during exercise in patients with chronic heart failure [116,148], as well as reversing endothelial dysfunction in patients with metabolic syndrome [149], suggesting its therapeutic potential for human patients suffering from cardiovascular and circulatory disorders. The gene discussed is GHRL; the disease is metabolic syndrome.